Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis.
- EligibilityCriteria: Inclusion Criteria:  Age ≥18 years Histologically or cytopathological confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy LVEF≥53% before chemotherapy  Exclusion Criteria:  life expectancy ≤12 months Participating in other ongoing oncology clinical trials Prior treatment with anthracyclines or chest radiation therapy Pregnant or lactating women Ultrasound images of the heart are of very poor quality - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Breast cancer patients with anthracycline-based breast cancer chemotherap - SamplingMethod: Probability Sample